UIC Barcelona and AB Biotics join forces to research probiotics
The University and the cutting-edge biotechnology company have signed a partnership agreement to work together on the programme investigating polyphosphate and the probiotic mechanism of action
From left to right: Miquel Àngel Bonachera, Sergi Audivert, Jordi Espadaler, Erola Astó, David Buj and Elisabet Navarro from AB Biotics next to Dr Josep Clotet, Dr Samuel Bru and Dr Javier Jiménez from UIC Barcelona.
The cutting-edge biotechnology company, AB Biotics, and the Universitat Internacional de Catalunya have signed a partnership agreement to develop research projects which will contribute to improving people’s health and well-being.
Specifically, both organisations will work together to develop a programme investigating polyphosphate and the probiotic mechanism of action. The main aim of this programme is to study the bacterial production of polyphosphate granules as a tool to improve symptoms associated with irritable bowel syndrome, which occurs in 10-15% of Europe’s population. The programme will also study the metabolic characterisation of over 500 bacterial strains in order to select the most appropriate ones to fight off different human diseases.
AB Biotics will be able to harness the expertise and experience studying polyphosphates of the UIC Barcelona research group “New Cyclins”, led by Dr Josep Clotet, to develop this initiative. The partnership will be developed in the recently-opened Biomedicine Laboratory at the University, located on the Sant Cugat campus.